SCHEMBL207832

SCHEMBL207832

[C]1=Cc2ccccc2NN=N1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18935280 0.70 GAA (0.36) GAAMAPT
SCHEMBL3089880 0.67 GAA (0.37) GAAMAPT
SCHEMBL8527496 0.67 GAA (0.33) GAAMAPT
SCHEMBL136053 0.66 NOX1 (0.38) GAAMAPT
SCHEMBL2299949 0.64 GAA (0.44) GAAMAPT
SCHEMBL31471662 0.62 GAA (0.33) GAAMAPT
Ammonia Solution, Strong SCHEMBL8637562 0.62 GAA (0.43) GAAMAPT
SCHEMBL6249625 0.61 GAA (0.32) GAAMAPT
SCHEMBL55652 0.58 GAA (0.43) GAAMAPT
SCHEMBL131587 0.58 GAA (0.37) GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US claimed
US-7576135-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US claimed
EP-1864982-A1 TRIAMINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-12 EP claimed
US-20070129371-A1 Novel ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 US claimed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US claimed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US claimed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP claimed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP claimed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US claimed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US claimed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP claimed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP claimed
US-20240231224-A9 HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF LAM RESEARCH CORPORATION 2024-07-11 US disclosed
WO-2024137876-A2 SURFACE MODIFICATION OF METAL CATALYSTS WITH HYDROPHOBIC LIGANDS OR IONOMERS TWELVE BENEFIT CORPORATION (US) 2024-06-27 WO disclosed
US-20240200208-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS SUMITOMO MITSUI BANKING CORPORATION 2024-06-20 US disclosed
WO-2024123514-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS TWELVE BENEFIT CORPORATION (US) 2024-06-13 WO disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129371-A1 Novel ethylenediamine derivatives C1R, C9, C1S GAA 4796/4885MAPT 4390/4885
US-20090239857-A1 TRIAMINE DERIVATIVE F2, F12, F3 GAA 4233/4885MAPT 4836/4885
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 GAA 4757/4885MAPT 4451/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R GAA 4788/4885MAPT 4271/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R GAA 4788/4885MAPT 4271/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R GAA 4788/4885MAPT 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.